Bioventus Inc.
BVS
$7.74
$0.101.31%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.08% | 8.60% | 11.89% | 10.40% | 5.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.08% | 8.60% | 11.89% | 10.40% | 5.14% |
| Cost of Revenue | 1.71% | 2.61% | 0.49% | -1.87% | -4.84% |
| Gross Profit | 6.77% | 11.75% | 18.29% | 17.65% | 11.00% |
| SG&A Expenses | 2.90% | 7.76% | 8.76% | 6.40% | -0.31% |
| Depreciation & Amortization | -16.67% | -11.55% | -13.46% | -3.59% | 0.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.12% | 5.79% | 5.25% | 2.60% | -2.79% |
| Operating Income | 66.41% | 78.82% | 1,685.34% | 344.84% | 251.76% |
| Income Before Tax | 103.61% | -87.63% | 57.37% | 58.48% | 76.22% |
| Income Tax Expenses | 131.68% | -653.16% | -6,327.06% | 34.90% | 83.65% |
| Earnings from Continuing Operations | 100.37% | -57.04% | 61.77% | 60.25% | 74.90% |
| Earnings from Discontinued Operations | -- | -- | -- | 100.00% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -102.82% | 78.55% | -55.90% | -60.87% | -77.40% |
| Net Income | 99.64% | -51.57% | 77.24% | 77.21% | 84.46% |
| EBIT | 66.41% | 78.82% | 1,685.34% | 344.84% | 251.76% |
| EBITDA | 17.07% | 16.31% | 45.63% | 25.94% | 36.00% |
| EPS Basic | 99.42% | -48.25% | 77.92% | 77.87% | 84.88% |
| Normalized Basic EPS | 52.04% | 231.18% | 3,850.00% | 134.08% | -78.84% |
| EPS Diluted | 99.10% | -48.25% | 77.92% | 77.87% | 84.88% |
| Normalized Diluted EPS | 47.53% | 231.18% | 3,850.00% | 134.08% | -78.84% |
| Average Basic Shares Outstanding | 3.89% | 3.54% | 3.01% | 2.55% | 2.05% |
| Average Diluted Shares Outstanding | 4.69% | 3.54% | 3.01% | 2.55% | 2.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |